Prosecution Insights
Last updated: November 20, 2026
Application No. 18/336,776

Pegylated-AU(III) Reagents for Rapid Cysteine S-Arylation of Biomolecules

Final Rejection §102§103§112
Filed
Jun 16, 2023
Examiner
PAGANO, ALEXANDER R
Art Unit
1692
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
2 (Final)
79%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
859 granted / 1093 resolved
+18.6% vs TC avg
Moderate +12% lift
Without
With
+11.7%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
46 currently pending
Career history
1147
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
23.0%
-17.0% vs TC avg
§102
31.4%
-8.6% vs TC avg
§112
26.3%
-13.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1093 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-27 of H. Maynard et al., US 18/366,766 (Mar. 29, 2021) are pending. Claims 11-21 drawn to non-elected Groups (II)-(III) are withdrawn from consideration pursuant to 37 CFR 1.142(b). Claims 1-10 and 22-27 are under examination on the merits. Claims 1-10, 22, and 24-27 are rejected. Claim 23 is objectionable. Election/Restrictions Pursuant to the restriction requirement, Applicant elected Group (I) (claims 1-10), without traverse, drawn to a composition comprising a polypeptide having at least one cysteine residue and a gold(III) aryl complex, the gold(III) aryl complex comprising a polyethylene glycol group, in the response filed on January 27, 2026. New claims 22-27 are added to the invention of Group (I). Claims 11-21 drawn to non-elected Groups (II)-(III) are withdrawn from consideration pursuant to 37 CFR 1.142(b). The restriction requirement is made FINAL Claim Objections Claim 23 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Withdrawal Claim Rejections - 35 USC § 102 (AIA ) Rejection of claims 1-10 under 35 U.S.C. 102(a)(1) as being anticipated by H. Montgomery et al., 33 Bioconjugate Chemistry, 1536-1542 (published August 8, 2022) (“Montgomery”) is withdrawn. Montgomery is effective prior art under 35 USC § 102(a)(1) because it was published on August 8, 2022, less than one year before the instant effective filing date of June 16, 2023. Montgomery appears to name the additional author “Hayden R. Montgomery” over the instant inventorship. Applicant submits the Declaration of Heather D. Maynard under 37 CFR § 1.130 (Aug. 13, 2026) (the “Maynard Declaration”). The Maynard Declaration shows sufficient facts, in weight and character, to establish that the Montgomery disclosure was made by the inventor or a joint inventor.1 The Maynard Declaration otherwise meets the formal requirements. MPEP § 717.01(c). The rejection is withdrawn because Montgomery is not prior art. Withdrawal Claim Rejections 35 U.S.C. 112(a) – Written Description Rejection of claim 10 under 35 U.S.C. 112(a) as failing to comply with the written description requirement is withdrawn in view of Applicant’s argument. Applicant argues that the claimed function, reaction with a polypeptide having at least one cysteine residue, is generally related to the chemical reactivity of the gold(III) center toward sulfur as found in a thiol group. Reply at page 6. Applicant argues that all compounds within the claimed genus share a common gold(III) aryl framework. Reply at page 6. Applicant concludes that the claimed functionality is reasonably expected to be present across compounds sharing the recited gold(III) aryl framework. Reply at page 6. The Examiner agrees that the art teaches that gold readily complexes with cysteine residues, generally. See e.g., B. Söptei et al., 470 Colloids and Surfaces A: Physicochem. Eng. Aspects, 8-14 (2015) (“Söptei”) (see page 9 at col. 1, stating “It is known that cysteine residues reduce Au3+ to form Au+ species”). As such, one of skill in the art would recognize Applicant was in possession of the claim 10 claimed gold (III) aryl complex comprising a polyethylene glycol group function conjugated to polypeptide having at least one cysteine residue. Accordingly, the rejection with withdrawn. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under AIA 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-10, 22, and 24-27 are rejected under AIA 35 U.S.C. 103 as being unpatentable over M. Messina et al., 140 Journal of the American Chemical Society, 7065-7069 (2018) (“Messina”) in view of F. Veronese et al., 22 Biodrugs, 315-319 (2008) (“Veronese”); J. Harris et al., 2 Nature Review Drug Discovery, 241-221 (2003) (“Harris); and A. Wijesinghe et al., PLOS ONE, 1-19 (2022) (“Wijesinghe”). M. Messina et al., 140 Journal of the American Chemical Society, 7065-7069 (2018) (“Messina”) Messina teaches an efficient method for chemoselective cysteine arylation of unprotected peptides and proteins using Au(III) organometallic complexes. Messina at Abstract. Messina teaches the following general equation for C−S bond formation in the disclosed cysteine arylation processes. PNG media_image1.png 200 400 media_image1.png Greyscale Messina at page 7065, col. 2. Messina teaches pegylated gold complex 2o (see structural depiction of 2o below). Messina at page 7066, col. 2, Fig. 2. Messina teaches that under the optimized bioconjugation conditions (25 °C, 3 equiv Au complex, 80:20 H2O : MeCN, 0.1 M Tris buffer, pH 8.0), a quantitative conversion to the GSH S-aryl conjugates was observed for substrate 2o in <5 min. Messina at page 7066, col. 2, last paragraph. In the supplementary materials, Messina teaches the corresponding experimental for cysteine arylation using pegylated gold complex 2o. Cysteine arylation using compound 2o: To a 2 mL Eppendorf tube was added 50 μL of peptide stock solution in 200 mM Tris pH 8.0. To this solution was added 50 μL of a 6 mM gold reagent stock solution in water (MilliQ), and the Eppendorf tube was vortexed (<5 seconds). At one min, a 20 μL aliquot was removed and diluted in a 100 μL solution of 1:1 H2O:MeCN with 0.1% mol TFA. An aliquot from this solution was analyzed via LCMS. Messina at page S129. The Examiner summarizes Messina’s cysteine arylation of tripeptide glutathione (i.e., Glu-Cys-Gly)2, using substrate 2o, as follows: PNG media_image2.png 200 400 media_image2.png Greyscale Messina at page 7066, col. 2, last paragraph; Id. at page S129. Messina further teaches di-pegylation of the two accessible cysteine residues of fibroblast growth factor 2 FGF2 using 2o. Messina at page S139, Figure S102. Fibroblast growth factor 2 (FGF-2) is a small 18 kDa protein with clinical potential for ischemic heart disease, wound healing, and spinal cord injury. T. Lühmann et al., 6 ACS Biomaterials Science & Engineering, 425-432 (2020). Differences between Messina and Claim 1 Messina teaches (per claim 1) a composition (i.e., a reaction mixture) comprising a polypeptide having at least one cysteine residue and a gold(III) aryl complex, the gold(III) aryl complex comprising a polyethylene glycol group. Messina differs from claim 1 only in that the polyethylene glycol (PEG) group of the gold (III) aryl complex 2o has a molecular weight of 0.550 kDa, whereas claim 1 requires a PEG “having an average molecular weight greater than 1 kDa”. F. Veronese et al., 22 Biodrugs, 315-319 (2008) (“Veronese”) As summarized below, Veronese teaches that for PEGylated proteins and peptides, the molecular weight of the polyethylene glycol chain is a result-effective variable, where PEG molecular weights in the range of 5 to 50 kDa generally being employed in FDA approved conjugates. Veronese teaches that the precise structure of peptides allows them to play important roles as activators or inhibitors of biological mechanisms, or as biocatalysts in metabolic processes are therefore an obvious choice as new therapeutic agents. Veronese at page 315, col. 1. Veronese teaches that the intrinsic properties of these macromolecules, however, present drawbacks that limit their administration, such as instability, degradation by proteolytic enzymes, rapid excretion, and potential immunogenicity. Veronese at page 316, col. 1. Veronese teaches that PEG conjugation to peptides improves solubility, and the conjugates become resistant to antibodies, proteolytic enzymes and cells, and, because of their increased size (figure 1), are ultra-filtered by the kidneys more slowly. Veronese at page 316, col. 2. Veronese teaches that cysteine thiol residues, when present, are also very convenient because, being seldom present in proteins, they allow site-specific conjugation; furthermore, they can be conveniently introduced by genetic engineering at desired sites in the sequence. Veronese at page 316, col. 2. Veronese teaches a listing of PEGylated proteins or oligonucleotides approved by the US FDA, where the molecular weight range of the PEG is 5 kDa – 40 kDa. Veronese at page 318, Table II. Veronese teaches that the size of the polymer plays a significant role in determining the biological behavior of PEG conjugates. Veronese at page 320, col. 2. Veronese teaches that the mass of bound PEG is important for determining the time it remains in the blood and the required mass can be reached by adding either several small PEG chains to the protein, or alternatively one PEG chain of high mass. Veronese at page 320, col. 2. Veronese teaches that pharmaceutical grade PEG should have a polydispersity spanning from 1.01 for a product of 5 kDa, up to 1.1 for a product of 50 kDa. Veronese at page 320, col. 2. J. Harris et al., 2 Nature Review Drug Discovery, 241-221 (2003) (“Harris) Harris provides similar teaches to Veronese. Harris teaches pegylating site-specifically can minimize the loss of biological activity and reduce immunogenicity. Harris at page 216, col. 2. Harris teaches that because there are far fewer cysteine residues than lysine groups on polypeptides, the THIOL groups of cysteine are ideal for specific modifications and moreover, cysteines can be added to polypeptides precisely where they are desired by genetic engineering. Harris at page 216, col. 2. A. Wijesinghe et al., PLOS ONE, 1-19 (2022) (“Wijesinghe”) Wijesinghe teaches that while peptides can be excellent therapeutics for several conditions, their limited in vivo half-lives have been a major bottleneck in the development of therapeutic peptides. Conjugating the peptide to an inert chemical moiety is a strategy that has repeatedly proven to be successful in extending the half-life of some therapeutics. Wijesinghe at Abstract. Wijesinghe teaches that therapeutic molecules that are smaller than the threshold for renal filtration, which is thought to be ~70 kDa, are more likely to undergo faster renal clearance as compared to those that are larger. Wijesinghe at page 3, 1st full paragraph. Wijesinghe teaches that in the search for conjugates with favorable characteristics, researchers have observed that attaching moieties capable of increasing the peptide’s size and/or altering its charge has potential to successfully extend plasma half-life. Attaching a conjugate that is relatively large like PEG can increase the MW of the peptide by 2–40 kDa allowing it to evade kidney filtration. Wijesinghe at paragraph bridging pages 3-4. Obviousness Rationale Claim 1 is obvious because one of ordinary skill seeking to therapeutically employ and improve the pharmacokinetics of a cysteine-containing polypeptide is motivated to prepare a composition, comprising Messina’s gold (II) aryl complex 2o, but where 2o’s polyethylene glycol group is extended from n=10 to an average molecular weight greater than 2 kDa, in order to conjugate the polyethylene glycol group to the polypeptide as follows: Proposed Modification of Messina (employ higher molecular weight PEG) PNG media_image3.png 200 400 media_image3.png Greyscale One of ordinary skill is motivated to employ 2o (modified by PEG extension to greater than 2kDa) because Veronese, Harris and Wijesinghe teach that PEG conjugation improves peptide pharmacokinetics and that PEG molecular weights in the range of 5 kDa - 40 kDa represents an optimized pharmacokinetic range for pharmacokinetic/therapeutic efficacy. For example, Veronese teaches a listing of PEGylated proteins or oligonucleotides approved by the US FDA, where the molecular weight range of the PEG is 5 kDa – 40 kDa. Veronese at page 318, Table II. In another example, Wijesinghe teaches that attaching a conjugate that is relatively large like PEG can increase the MW of the peptide by 2–40 kDa allowing it to evade kidney filtration. Wijesinghe at paragraph bridging pages 3-4.3 One of ordinary skill has a reasonable expectation of success, because Messina teaches that a comprehensive demonstration of the aryl scope was performed with GSH under the optimized bioconjugation conditions (25 °C, 3 equiv. Au complex, 80:20 H2O:MeCN, 0.1 M Tris buffer, pH 8.0) and quantitative conversion to the GSH S-aryl conjugates was observed in <5 min for all 17 substrates displayed in Figure 2A (b−r), indicating to one of ordinary skill that the reaction is facile and general for cysteine-containing peptides. Messina at page 7066, col. 2. Still further, Messina teaches di-pegylation of the two accessible cysteine residues of fibroblast growth factor 2 (FGF2) using 2o. Messina at page S139, Figure S102. Claims 1 and 2 are obvious over the cited art. Respecting claims 3 and 4, In the supplementary materials, Messina teaches the corresponding experimental for cysteine arylation of glutathione (tripeptide sequence γ-Glu-Cys-Gly) using pegylated gold complex 2o. Cysteine arylation using compound 2o: To a 2 mL Eppendorf tube was added 50 μL of peptide stock solution [2 mM, see page S110]4 in 200 mM Tris pH 8.0. To this solution was added 50 μL of a 6 mM gold reagent stock solution in water (MilliQ), and the Eppendorf tube was vortexed (<5 seconds). At one min, a 20 μL aliquot was removed and diluted in a 100 μL solution of 1:1 H2O:MeCN with 0.1% mol TFA. An aliquot from this solution was analyzed via LCMS. Messina at page S129. Messina’s above-employed 50 μL of peptide stock solution is 2 mM (millimolar) glutathione. Messina at page S109, lines 7-8. Thus, the above composition (total volume 300 μL) contains 0.1 μmol of peptide and 0.3 μmol of gold complex. The molar ratio of gold (III) aryl complex to the peptide in the Messina composition is therefore 3 (which falls within the claim 3 concentration range, but outside the claim 4 concentration range), and which would be starting point for routine optimization.5 Here, claims 3 and 4 are obvious because one or ordinary skill is motivated to adjust the molar ratio of gold (III) aryl complex to polypeptide depending on the peptide employed (e.g., the number of available cysteine residues). Further, Messina’s molar ratio of 3 falls within the claim 3 range and is close to the claim 4 range of “between 1 and 2”. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. MPEP § 2144.05(I). Similarly, a prima facie case of obviousness exists where the claimed ranges or amounts do not overlap with the prior art but are merely close. Id. Claim 5 is obvious because numerous therapeutic polypeptides considerable for conjugation have a molecular weight greater than 10kDa. For example, Messina teaches di-pegylation of the two accessible cysteine residues of fibroblast growth factor 2 (FGF2) using 2o. Messina at page S139, Figure S102. Fibroblast growth factor 2 (FGF-2) is a small 18 kDa protein with clinical potential for ischemic heart disease, wound healing, and spinal cord injury. T. Lühmann et al., 6 ACS Biomaterials Science & Engineering, 425-432 (2020). The limitations of claim 6 are clearly met because the proposed mPEG-Au(III) complex is the same as that claimed, subject to PEG molecular weight. The limitations of claim 7 are met because Messina’s composition comprises “one or more of a reducing agent, a buffer, a salt, and solvent”. Per the above experimental excerpt Messina’s composition comprises “50 μL of peptide stock solution in 200 mM Tris pH 8.0”. Messina at page S129. Respecting claim 8, Messina teaches a pH of 8, which is close to, but outside the claim 8 range of 5.5 and 7.5. However, a prima facie case of obviousness exists where the claimed ranges or amounts do not overlap with the prior art but are merely close. MPEP § 2144.05(I). Here the concentration of H+ does not distinguish over the cited art. See footnote 3. Claim 9 recites: 9. The composition of claim 1, wherein the composition comprises more than 50 μM of the polypeptide. In the chemical arts molarity or moles per liter is indicated by a capital M. Claim 9 therefore literally reads as ‘comprises more than 50 μmols polypeptide per liter of the composition’. See e.g., Hawley's Condensed Chemical Dictionary, page 944 (16th ed., 2016, R.J. Larrañaga ed.). Messina teaches the corresponding experimental for cysteine arylation using pegylated gold complex 2o. Cysteine arylation using compound 2o: To a 2 mL Eppendorf tube was added 50 μL of peptide stock solution in 200 mM Tris pH 8.0. To this solution was added 50 μL of a 6 mM gold reagent stock solution in water (MilliQ), and the Eppendorf tube was vortexed (<5 seconds). At one min, a 20 μL aliquot was removed and diluted in a 100 μL solution of 1:1 H2O:MeCN with 0.1% mol TFA. An aliquot from this solution was analyzed via LCMS. Messina at page S129. Messina’s above-employed 50 μL of peptide stock solution is 2 mM glutathione. Messina at page S109, lines 7-8. Thus, the above composition (total volume 300 μL) contains 0.1 μmol of peptide and 0.3 μmol of gold complex. Thus, Messina’s composition comprises 0.1 μmol of peptide in the 300 μL, which is 333 μM and therefore meets the molarity limitations of claim 9. One of ordinary skill is therefore motivated by Messina’s disclosed peptide molarity (M) to optimize the polypeptide in the above-proposed method to within the claimed concentration range of “more than 50 μM of the polypeptide”. MPEP § 2144.05(II); see also above footnote 3. The limitations of claim 10 are met because in practice of the cited art as proposed the gold complex reacts with the poly peptide to form the PEG-aryl-polypeptide conjugate, which corresponds to the claim 10 “cysteine-aryl conjugated polypeptide”. In other words, at some time point after mixing the gold complex and polypeptide, the PEG-aryl-polypeptide conjugate will also be present; at least until and if the mPEG-Au(III) and DARPin are completely reacted. Thus, all three required claim 10 components are present in in the proposed composition. Claims 22 and 24-27 are obvious under the above rationale because Messina complex 2o meets the claim 22 alternative of 2-(di(alkyl)phosphino)-N,N-dimethylaniline, where in Messina complex 2o, the “alkyl” is the cycloalkyl group adamantanyl (i.e., species L1 of claim 27). Note that with respect to the genus of 2-(di(alkyl)phosphino)-N,N-dimethylaniline ligands, the specification defines the “alkyl” portion as including both alkyl and cycloalkyl. Specification at page 5, lines 24-25. That this definition applies is also evident from dependent claim 27. APPLICANT’S ARGUMENT Applicant proffers specification results as unexpected over Messina. Applicant argues that the specification working examples demonstrate unexpectedly efficient PEGarylation of DARPin (designed ankyrin repeat protein) sufficient to overcome the § 103 rejection. Reply at page 7. (i) The Proffered Results The cited specification working example teaches PEGarylation of DARPin (designed ankyrin repeat protein, having a single cysteine residue) having the following sequence: (SEQ ID NO:1) MGSDKIHHHHHHENLYFQGGCGGSDLGKKLLEAARAGQDDEVRILMANGADVNA YDDNGVTPLHLAAFLGHLEIVEVLLKYGADVNAADSWGTTPLHLAATWGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN (specification at page 19, lines 20-25) with the claimed Au(III) mPEG complex (2 kDa, 5 kDa or 10 kDa), according to the following procedure: Conjugation Condition Screening Standard conjugation conditions: (70 [Symbol font/0x6D]M DARPin, pH 7.5, 4 equiv. TCEP, 1.3 equiv. Au(III), 1 minute, 25 °C) To 50 [Symbol font/0x6D]L of a solution of 76 μM DARPin in 20 mM Tris, 150 mM NaCl buffer, pH 7.5, was added 5 [Symbol font/0x6D]L of a 3 mM stock solution of TCEP~HCl (4 equivalents) in MilliQ H2O. This solution was allowed to sit at 25 °C for one hour to reduce any disulfide bonds formed during storage. Then, 5 [Symbol font/0x6D]L of a 1 mM stock solution of Au(III) mPEG reagent (1.3 equivalents) in MilliQ H2O was added, gently flicked to mix and allowed to react for one minute. After one minute, the reaction was stopped by dilution in appropriate media for analysis (see below) or subjection to FPLC purification. Specification at page 21, lines 1-9. The proffered specification example is summarized by the Examiner as follows: PNG media_image4.png 200 400 media_image4.png Greyscale Per specification Table 1, the proffered working example results in greater than 90% conversion, for each of the 2 kDa, 5 kDa, and 10 kDa Au(III) mPEG reagent (1.3 equivalents) in one minute. Specification at pages 22-23 (Table 1). Applicant argues that with just 1.3 equivalents of the gold(III) PEG-aryl complex, PEGarylation of the proffered DARPin sequence occurred in less than 1 min. Reply at page 7. Applicant argues that the prior art provides no reasonable expectation that increasing the mass of the PEG aryl ligand would produce a catalyst having such an improved efficiency with regard to equivalents and reaction time. Reply at page 7. (ii) Prior Art Messina’s Results In one experiment, Messina teaches cysteine arylation of glutathione (tripeptide sequence γ-Glu-Cys-Gly) using pegylated gold complex 2o. Cysteine arylation using compound 2o: To a 2 mL Eppendorf tube was added 50 μL of peptide stock solution in 200 mM Tris pH 8.0 [2 mM glutathione solution, see page S110]6. To this solution was added 50 μL of a 6 mM gold reagent stock solution in water (MilliQ), and the Eppendorf tube was vortexed (<5 seconds). At one min, a 20 μL aliquot was removed and diluted in a 100 μL solution of 1:1 H2O:MeCN with 0.1% mol TFA. An aliquot from this solution was analyzed via LCMS. Messina at page S129 (emphasis added). Messina reports a 98% LCMS yields of the PEGarylated glutathione (i.e., quantitative conversion in one minute). Messina at page S129.7 Messina’s above-employed 50 μL of peptide stock solution is 2 mM glutathione. Messina at page S110. Thus, the above Messina reaction mixture contains 0.1 μmol of peptide and 0.3 μmol of gold complex or 3 equivalents of gold complex relative to the tripeptide glutathione. Messina thus teaches quantitative PEGyation of glutathione was completed in one minute with 3 equivalents of gold complex. Messina at page S129. Referencing Figure S102 at page S139, Messina teaches PEG arylation of fibroblast growth factor 2 (FGF2) with gold complex 2o (15 equiv) as follows. We next extended the scope of Au(III)-mediated cysteine bioconjugation to the modification of proteins. Cysteine arylation of DARPin (designed ankyrin repeat protein) was observed using complex 2a within 30 min at 25 °C, as verified by LC-MS analysis of the reaction mixture (Figure 3A). The presence of a small amount of DMF cosolvent (5%) was required for efficient bioconjugation due to the inherent solubility constraints of 2a. However, treatment of fibroblast growth factor 2 (FGF2) with water-soluble 2o (15 equiv) in aqueous buffer only resulted in complete conversion to the PEGylated conjugate as confirmed by the deconvoluted mass spectrum from LC-MS analysis of the reaction mixture (see SI Figure S102). The rapid and efficient protein bioconjugation reactions demonstrate the potential generality and suitability of the described Au(III)-mediated methodology for the modification of complex proteins under mild, biologically relevant conditions and at low micromolar concentration of protein (36 μM). Messina at page 7067, cols 1-2 (emphasis added) (referencing Figure S102 at page S139). Messina’s experimental procedure is reported at page S139 as follows: FGF2 Modification: 50 μL of a 0.66 μM solution of FGF2 in 200 mM Tris (pH 8.7) was added to an Eppendorf tube. To this solution was added 50 μL of a 9.93 μM solution of 2g in water. The reaction m mixture was pipetted 20 times to ensure proper mixing and allowed to stand at room temperature for 30 min. After 30 min, a 20 μL aliquot of the reaction mixture was added to 100 μL of a 50:50 water/acetonitrile 0.1% TFA solution. Messina at page S139. Thus, with the protein FGF2, Messina teaches complete conversion to the PEGylated conjugate occurred within 30 minutes with 15 equivalents of gold complex 2o. (iii) The Proffered Results Do Not Overcome the § 103 Rejection Applicant argues that with just 1.3 equivalents of the gold(III) PEG-aryl complex, PEGarylation of the proffered DARPin sequence occurred in less than 1 min. Reply at page 7. Applicant argues that the prior art provides no reasonable expectation that increasing the mass of the PEG aryl ligand would produce a catalyst having such an improved efficiency with regard to equivalents and reaction time. Reply at page 7. In response, Applicant’s argument does not appear relevant to a finding of unexpected results because the peptide sequences are different in the proffered versus prior art comparison.8 Contrary to Applicant’s argument, the Examiner cannot identify where Messina tests PEGylated gold complex 2o with any DARPin sequence, let alone the same DARPin sequence proffered by Applicant. See Reply at page 7. Rather, Messina PEGarylates either glutathione or FGF2 with gold complex 2o. Thus, for example, a relevant prior art comparison is PEGylation of the same DARPin sequence (i.e., specification SEQ ID NO:1) with Messina’s gold complex 2o versus the claimed PEGylated gold complex. Messina’s tested Fibroblast growth factor 2 (FGF-2) consists of 288 amino acids having four cysteine residues two of which are accessible, is structurally different than Applicant’s proffered 148 amino acid DARPin of SEQ ID NO:1, having only one cysteine residue.9 Applicant has not explained why the proffered result with a structurally different polypeptide is relevant to a finding of unexpected results. MPEP § 716.01(b). The burden is on Applicant to establish that the evidence relied upon demonstrates that the differences in results are in fact unexpected and unobvious and of both statistical and practical significance. MPEP § 716.02(b). The comparison of Messina’s PEGylation time of 30 minutes with 15 equivalents of gold complex for FGF2 versus the proffered result of 1 minute with 1.5 equivalents of gold complex with the proffered DARPin sequence is further not persuasive for the following reasons. It is not at all clear that Messina’s quantitative PEGylation was not completed faster than at the 30 minute mark, at which it was stopped, nor that Messina’s PEGylation could not have been effected with fewer equivalents of gold complex. The proffered result is further not unexpected because Messina teaches cysteine arylation of glutathione (tripeptide sequence γ-Glu-Cys-Gly) using pegylated gold complex 2o with 3 equivalents of gold complex in 1 minute. Messina at page S129. Each of the proffered DARPin peptide and prior art glutathione have one accessible cysteine residue. First note that it is not at all clear that Messina’s PEGylation could not have been effected with fewer than 3 equivalents of gold complex; particualry because the reaction is fast and quantitative. In any case, Applicant’s proffered PEGarylation of DARPin of 1.3 equivalents of a gold(III) PEG-aryl complex in less than 1 min is not unexpected, on its face, in view of Messina’s glutathione PEGarylation in 1 minute with 3 equivalents of PEGylated gold complex 2o. Furthermore, the proffered results with the single species of claimed Au(III) mPEG complex (2 kDa, 5 kDa or 10 kDa) are clearly not commensurate in scope with claims 1-5, 7-10, and 22-27, which claim larger genera of gold complexes. The objective evidence of nonobviousness must be commensurate in scope with the claims which the evidence is offered to support; that is, the showing of unexpected results must be reviewed to see if the results occur over the entire claimed range. MPEP § 716.02(d); In re Dill, 604 F.2d 1356, 1361 (CCPA 1979). The nonobviousness of a broader claimed range can be supported by evidence based on unexpected results from testing a narrower range if one of ordinary skill in the art would be able to determine a trend in the exemplified data which would allow the artisan to reasonably extend the probative value thereof. MPEP § 716.02(d)(I). Here no trend between the single proffered species and the full scope of gold complexes claimed can be determined and Applicant has offered no explanation on this point. MPEP § 716.02(d)(I). Subject Matter Free of the Art of Record Claim 23 is free of the art of record. Claim 23 is directed to the composition of claim 1, wherein the gold(III) aryl complex comprises a bidentate ligand selected from the group consisting of 2-(di(alkyl)phosphino)-N,Ndimethylaniline and 2-(di(alkyl)phosphino)-phenyl]morpholine and the alkyl group is tert-butyl. The closest prior art is M. Messina et al., 140 Journal of the American Chemical Society, 7065-7069 (2018) (“Messina”). As discussed above, Messina teaches the following 2-(di(adamantanyl)phosphino)-N,Ndimethylaniline (pegylated gold complex 2o). PNG media_image5.png 200 400 media_image5.png Greyscale Messina teaches that this PEGylated gold complex is useful for chemoselective cysteine arylation of unprotected peptides and proteins. Messina at Abstract. Difference between Messina and Claim 23 Messina differs from claim 23 in that it comprises two adamantanyl groups on the phosphorous atom, whereas claim 23 requires two tert-butyl groups at this position. Claim 23 Is Not Obvious in View of Messina Obviousness of a claimed compound can also be supported where there is motivation to substitute particular chemical moieties in a prior art compound for others so as to arrive at a claimed compound. MPEP § 2143(I)(B). For example, in the chemical arts, the rationale is stated as motivation to select a known compound and also motivation to structurally modify the selected compound in a particular way to achieve a claimed compound. MPEP § 2143(I)(B) (see for example, MPEP § 2143(I)(B) Example 9, citing Eisai Co. Ltd. v. Dr. Reddy’s Labs., Ltd., 533 F.3d 1353, 87 USPQ2d 1452 (Fed. Cir. 2008). Here, neither Messina nor secondary art motivates one of ordinary skill to replace Messina’s two adamantanyl groups of pegylated gold complex 2o with tert-butyl groups. Further, neither Messina nor secondary art provides a reasonably expectation that such tert-butyl substituted gold complex would be effective for chemoselective cysteine arylation of unprotected peptides and proteins. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALEXANDER R PAGANO whose telephone number is (571)270-3764. The examiner can normally be reached 8:00 AM through 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ALEXANDER R. PAGANO Examiner Art Unit 1692 /ALEXANDER R PAGANO/Primary Examiner, Art Unit 1692 1 An "unequivocal" statement from the inventor or a joint inventor that he/she (or some specific combination of named joint inventors) invented the subject matter of the disclosure, accompanied by a reasonable explanation of the presence of additional authors, may be acceptable in the absence of evidence to the contrary. MPEP § 717.01(a)(1) (citing In re DeBaun, 687 F.2d 459, 463, 214 USPQ 933, 936 (CCPA 1982)). 2 Messina’s tripeptide glutathione meets the meaning of claim 1 “polypeptide”. The specification defines “polypeptide” as follows: Disclosed herein is a composition comprising a polypeptide having at least one residue having a free thiol (e.g., cysteine) and a gold(III) aryl complex. The polypeptide can be a protein or fragment thereof, for example an enzyme, hormone, structural protein, storage protein, contractile protein, an antibody, or an immunoglobulin. The polypeptide can comprise a multiplicity of amino acids residues. Polypeptides may have 10, 50, 100, 150, 200, or 250 or more amino acid residues. Specification at page 5, lines 9-14 (emphasis added). 3 One of ordinary skill is motivated to develop workable or optimum ranges for result-effective parameters, where Applicant can rebut a prima facie case of obviousness by showing the criticality (unexpected result) of the range. MPEP § 2144.05; see also, In re Boesch, 617 F.2d 272,276 (CCPA 1980); In re Aller, 220 F.2d 454, 456 (CCPA 1955). 4 Messina teaches that the glutathione stock solution is a 2 mM solution of glutathione prepared in 200 mM pH 8.0 Tris buffer. Messina at page S110. 5 Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. MPEP § 2144.05(II)(A) (citing In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). 6 Messina teaches that the glutathione stock solution is a 2 mM solution of glutathione prepared in 200 mM pH 8.0 Tris buffer. Messina at page S110. 7 Messina teaches that “quantitative conversion to the GSH S-aryl conjugates was observed in <5 min for all 17 substrates displayed in Figure 2A (b−r)”. Messina t page 7066, col. 2 (emphasis added). 8 If the evidence is to be given substantial weight in the determination of obviousness or nonobviousness, evidence of secondary considerations must be relevant to the subject matter as claimed, and therefore the examiner must determine whether there is a nexus between the merits of the claimed invention and the evidence of secondary considerations. MPEP § 716.01(b) (citing Ashland Oil, Inc. v. Delta Resins & Refractories, Inc., 776 F.2d 281, 305 n.42, 227 USPQ 657, 673-674 n. 42 (Fed. Cir. 1985)). 9 Fibroblast growth factor 2 (FGF-2) is an 18 kDa protein and consists of 12 anti-parallel ß-sheets organized into a trigonal pyrimidal structure. M. Nugent et al., 32 The International Journal of Biochemistry & Cell Biology, 115-120 (2000) (“Nugent”). Nugent teaches that FGF2 has four cysteine residues. Nugent at page 116, col. 1. Messina teaches that two of these residues appear to be accessible for di-PEGylation reaction with Messina’s gold complex 2o. Messina at page S139.
Read full office action

Prosecution Timeline

Jun 16, 2023
Application Filed
Mar 12, 2026
Non-Final Rejection mailed — §102, §103, §112
Aug 31, 2026
Response after Non-Final Action
Aug 31, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780861
PYRAZOLE COBALT-BASED METAL-ORGANIC FRAMEWORK MATERIAL WITH DYNAMIC PORE SIZE, METHOD FOR MAKING THE SAME, AND USE IN SULFUR HEXAFLUORIDE CAPTURE
1y 12m to grant Granted Nov 03, 2026
Patent 12774263
RECYCLE CONTENT (C4)ALKANOIC ACID
4y 9m to grant Granted Oct 27, 2026
Patent 12767672
METHODS TO PRODUCE ORGANOTIN COMPOSITIONS WITH CONVENIENT LIGAND PROVIDING REACTANTS
12m to grant Granted Oct 20, 2026
Patent 12760046
NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS
3y 0m to grant Granted Oct 13, 2026
Patent 12753323
FLUORINE-CONTAINING ETHER COMPOUND, SURFACE TREATMENT AGENT, FLUORINE-CONTAINING ETHER COMPOSITION, COATING LIQUID, ARTICLE, AND COMPOUND
4y 6m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
79%
Grant Probability
90%
With Interview (+11.7%)
2y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1093 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month